NVO announcements Novo Nordisk A/s announcements and dividends declared USA
Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO
Novo Nordisk A/s NVO listed on USA and deals in Health Care Major PharmaceuticalsAnnouncements and dividends declared by Novo Nordisk A/s NVO
Generic drug companies rework pricing to gain weight in India’s GLP-1 market as Novo Nordisk slashes Wegovy prices
Indian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting generic companies to lower their expected launch prices. Novo Nordisk is also preparing to launch Ozempic in India s
Announcement as on 26 November 2025
Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
Novo Nordisk said its new experimental obesity drug, amycretin, delivered up to 14.5% weight loss at 36 weeks in type 2 diabetes patients in a mid-stage trial. The drug was found to be safe with mostly mild gastrointestinal side effects, and the company pl
Announcement as on 25 November 2025
Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya
Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring
Announcement as on 19 November 2025
Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India
Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative thera
Announcement as on 18 November 2025
Novo Nordisk slashes Wegovy prices in India by up to 37% to boost sluggish sales of weight-loss drug
According to renowned endocrinologist Dr Shashank Joshi, a steep cut in the prices of Wegovy will help improve access and affordability. “But it has to be cautioned that weight loss drugs are not cosmetic medicines. It has to be prescribed to the right pat
Announcement as on 11 November 2025
Announcements by Novo Nordisk A/s first page | Next page | Prev page |
NVO Novo Nordisk A/s current price & indicator signals
Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 08 Mon Dec 2025 | 46.77 | 46.35 to 47.17 | -2.26% | 0.82 times |
| 05 Fri Dec 2025 | 47.85 | 47.83 to 49.15 | -0.29% | 0.5 times |
| 04 Thu Dec 2025 | 47.99 | 46.84 to 48.24 | 0.88% | 0.75 times |
| 03 Wed Dec 2025 | 47.57 | 47.30 to 48.11 | 0.27% | 0.64 times |
| 02 Tue Dec 2025 | 47.44 | 47.37 to 48.87 | -2.04% | 0.52 times |
| 01 Mon Dec 2025 | 48.43 | 48.37 to 49.49 | -1.86% | 0.65 times |
| 28 Fri Nov 2025 | 49.35 | 48.35 to 49.71 | 1.36% | 0.86 times |
| 26 Wed Nov 2025 | 48.69 | 46.50 to 49.03 | 3.49% | 0.75 times |
| 25 Tue Nov 2025 | 47.05 | 44.22 to 47.21 | 4.58% | 1.22 times |
| 24 Mon Nov 2025 | 44.99 | 41.25 to 48.01 | -5.54% | 3.06 times |
| 21 Fri Nov 2025 | 47.63 | 46.69 to 48.15 | 0.06% | 1.06 times |
| 20 Thu Nov 2025 | 47.60 | 47.48 to 49.53 | -2.86% | 0.85 times |
Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared USA
Hindi Video Most Important Stock Market Video. No Success Without This Formula
Hindi Video What Is Needed To Succeed In Stock Markets
- USA Screeners
- USA Daily Screener
- USA Weekly Screener
- USA Monthly Screener
- Support & Resistance
- USA Shares Near Support
- USA Shares Near Resistance


